Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · OS Therapies Inc (OSTX)

OS Therapies Files Prospectus Supplement for Resale of 5,874,094 Shares

Neutral Impact 2 of 5 shareholder Written later

OS Therapies filed a prospectus supplement covering the resale of up to 5,874,094 common shares by selling stockholders under its effective Form S-3 registration statement. This 8-K provides the legal opinion from its counsel on the legality of those shares.

Key points

  • Prospectus supplement filed September 10, 2026 under Form S-3 (File No. 333-289443), filed August 8, 2025 and declared effective August 25, 2025
  • Covers resale of up to 5,874,094 common shares by selling stockholders
  • Legal opinion from Olshan Frome Wolosky LLP attached as Exhibit 5.1

The filing

CompanyOS Therapies Inc (OSTX)
Form8-K, current report
Filed with the SECSep 10, 2026, 5:28 PM ET
Accession number0001213900-26-098880

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.